1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Swedish Orphan Biovitrum AB (publ)
  6. News
  7. All News
    SOBI   SE0000872095

SWEDISH ORPHAN BIOVITRUM AB (PUBL)

(SOBI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
All news about SWEDISH ORPHAN BIOVITRUM AB (PUBL)
05/10Bulletin from Swedish Orphan Biovitrum (Sobi®)'s Annual General Meeting (AGM)
AQ
05/10Swedish Orphan Biovitrum AB Elects Bo Jesper Hansen as New Board Member
CI
04/28Swedish Orphan Biovitrum AB Reports Earnings Results for the First Quarter Ended March ..
CI
04/28TRANSCRIPT : Swedish Orphan Biovitrum AB, Q1 2022 Earnings Call, Apr 28, 2022
CI
04/28Swedish Drugmaker Sobi Confirms FY22 Revenue Outlook After Q1 Growth
MT
04/28Drugmaker Sobi books profit fall on restructuring, Russia
RE
04/28Sobi publishes Q1 2022 report
AQ
04/28Swedish Orphan Biovitrum AB Provides Earnings Guidance for the Year 2022
CI
04/20INVITATION : Sobi's Q1 2022 report
AQ
04/06Swedish Orphan Biovitrum AB - Annual and Sustainability Report 2021
AQ
04/06Swedish Orphan Biovitrum AB - Notice of Annual General Meeting in Swedish Orphan Biovit..
AQ
04/05Sobi publishes 2021 Annual and Sustainability Report
AQ
04/05Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
AQ
03/29SOBI Starts Collaboration With SelectImmune Pharma Over Kineret Drug
MT
03/29SelectImmune Pharma Signs Collaboration Agreement with Swedish Orphan Biovitrum AB
CI
03/23Sobi to End Manufacturing Deal With Pfizer Early; 80 Stockholm Jobs Impacted
MT
03/23Sobi Announces Contract with Pfizer for the Manufacture of Drug Substance for ReFacto A..
CI
03/23Sobi to cease ReFacto manufacturing in the first quarter of 2024
AQ
03/18SOBI Receives Approval For Use Of Gamifant In China
MT
03/18Gamifant approved in China for the treatment of primary haemophagocytic lymphohistiocyt..
AQ
03/18Gamifant Gets Approval in China for the Treatment of Primary Haemophagocytic Lymphohist..
CI
03/09Sanofi, Swedish Orphan Biovitrum Say Efanesoctocog Alfa Prevents Bleeds During Phase 3 ..
MT
03/09Sanofi Says New Hemophilia Drug Met Primary, Secondary Endpoints in Study
DJ
03/09Sanofi, Swedish Orphan Biovitrum's Hemophilia Drug Shows Prevention Of Bleeding Episode..
MT
03/09Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in haemophi..
AQ
02/25Swedish Orphan Biovitrum's Haemophagocytic Lymphohistiocytosis Drug Gets Treatment Reco..
MT
02/25Gamifant (emapalumab) recommended for approval in China for treatment of primary haemop..
AQ
02/25Gamifant Recommends for Approval in China for Treatment of Primary Haemophagocytic Lymp..
CI
02/18GSK pauses trial of respiratory virus vaccine in pregnant women
RE
02/11Swedish Orphan Biovitrum - Sobi publishes Q4 and FY 2021 report
AQ
02/10TRANSCRIPT : Swedish Orphan Biovitrum AB, Q4 2021 Earnings Call, Feb 10, 2022
CI
02/10Swedish Orphan Biovitrum Expects Revenue Growth in 2022 Amid Expansion Plans
MT
02/10Sobi publishes Q4 and FY 2021 report
AQ
02/10Swedish Orphan Biovitrum AB Reports Earnings Results for the Fourth Quarter Ended Decem..
CI
02/10Swedish Orphan Biovitrum AB Reports Earnings Results for the Full Year Ended December 3..
CI
02/03INVITATION : Sobi's Q4 and FY 2021 report
AQ
02/02Sobi to present new data at EAHAD 2022
AQ
01/26Barclays, Deutsche Bank to Book $120 Million Losses on Failed Sobi Takeover
MT
01/26Barclays, Morgan Stanley, Deutsche Bank Reportedly Took Losses on Scrapped Advent Offer
MT
01/11Avalo Therapeutics Appoints Chief Commercial Officer
MT
2021Swedish Orphan Biovitrum Gets Positive Opinion From European Medicines Agency For COVID..
MT
2021Kineret® (anakinra) receives positive opinion from the CHMP for treatment of patients w..
AQ
2021Kineret® Receives Positive Opinion from the Committee for Medicinal Products for Human ..
CI
2021Swedish Orphan Biovitrum, Apellis Pharmaceuticals Win European Regulatory Nod For Blood..
MT
2021Apellis Pharmaceuticals Receives Approval From European Commission for Aspaveli
MT
2021Aspaveli® (pegcetacoplan) approved in EU as orphan drug for treatment of PNH
AQ
2021Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB Announce EU Approval of A..
CI
2021Swedish Orphan Biovitrum's Rare Blood Disease Therapy Achieves Haemoglobin Normalizatio..
MT
2021Apellis Pharmaceuticals Reports 46% Hemoglobin Normalization in Broad Paroxysmal Noctur..
MT
2021Aspaveli®/Empaveli™ (pegcetacoplan) demonstrated sustained normalisation of clini..
AQ
2021Swedish Orphan Biovitrum AB and Apellis Pharmaceuticals, Inc. Announces New Data Demons..
CI
2021Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB Report Empaveli™ Dem..
CI
2021Sobi continues the R&D transformation - Anders Ullman appointed new Head of R&D
AQ
2021Swedish Orphan Biovitrum AB Announces Executive Changes
CI
2021European Stocks Close Lower After Disappointing US Jobs Data
MT
2021FTSE Closes Down Amid Persistent Growth Fears
DJ
2021FTSE Edges Higher, Wickes's Margin Outperformance Leads to Further Upgrades
DJ
2021Statement by the Board of Directors in relation to the withdrawal of the public cash of..
AQ
2021FTSE Edges Higher, Service Sector Kept Growth Momentum in November
DJ
2021EUROPEAN MIDDAY BRIEFING - Stocks Flat as Oil Rises
DJ
2021Sobi Down 23% After AstraZeneca Said to Block Advent, GIC's Takeover Bid
MT
2021European shares end bumpy week with losses
RE
2021London Shares Rise in Early Trade; Oil Stocks Gain
DJ
2021Investor Says Advent, GIC Withdraw $7.6 Billion Takeover Bid For Sobi
MT
2021ADVENT INTERNATIONAL CORPORATION AND : SOBI) from Investor AB (OM:INVE A), AP Fonden 4 and..
CI
2021Selecta Biosciences, Swedish Orphan Biovitrum Complete Enrollment in Phase 3 SEL-212 St..
MT
2021Swedish Orphan Biovitrum, Selecta Biosciences Complete Enrolment In Gout Treatment Stud..
MT
2021Sobi and Selecta Biosciences announce completion of enrolment in DISSOLVE Phase 3 study..
AQ
2021Advent, GIC Agree Final Extension of Acceptance Period in Sobi Takeover
MT
2021Advent, GIC Waive Conditions on Sobi Takeover, Acceptance Period Extended Anew
MT
2021Advent, GIC Further Extend Acceptance Period for Sobi Takeover
MT
2021Sobi to present new data at the ASH 2021 Annual Meeting
AQ
2021SWEDISH ORPHAN BIOVITRUM : Sobi publishes report for the third quarter 2021
AQ
2021SWEDISH ORPHAN BIOVITRUM : Advent, GIC Extend Acceptance Period for Sobi Takeover
MT
2021SWEDISH ORPHAN BIOVITRUM : Sobi publishes report for the third quarter 2021
AQ
1  2  3  4  5  6  7  8  9Next
Upcoming event on SWEDISH ORPHAN BIOVITRUM AB (PUBL)